This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Valenti, R. Articles by Rivoltini, L. Search for Related Content PubMed PubMed Citation Articles by Valenti, R. Articles by Rivoltini, L. Related Collections Tumor Biology Tumor Biology: Inflammation and Immune Escape

Tumor-Released Microvesicles as Vehicles of Immunosuppression

Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

Requests for reprints: Licia Rivoltini, Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. Phone: 39-22390-3245; Fax: 39-22390-2154; E-mail: licia.rivoltini{at}istitutotumori.mi.it.

Tumor-released microvesicles, or exosomes, which are abundant in the body fluids of patients with cancer, are likely to be involved in tumor progression. We recently showed that microvesicles released by human melanoma and colorectal carcinoma cells can promote the differentiation of monocytes to myeloid-derived suppressor cells which support tumoral growth and immune escape. These findings underscore an important role for these extracellular organelles in remodeling tumor-stromal interactions to promote malignancy. [Cancer Res 2007;67(7):2912–5]

This article has been cited by other articles:

				P. Filipazzi, C. Castelli, V. Roberta, V. Huber, M. Iero, L. Pilla, L. Rivoltini, and G. Parmiani In Reply J. Clin. Oncol., October 10, 2007; 25(29): 4696 - 4697. [Full Text] [PDF]

				G. C. Prendergast This month in Cancer Reviews Online: Cancer risk factors, progression mechanisms, and targeted drug studies Cancer Reviews Online Content, May 1, 2007; 2007(2): 3 - 4. [Full Text] [PDF]